文献速递胃肠外科

使用hinotori™手术机器人系统进行胃癌机器人胃切除术的首次临床经验

First clinical experiences of robotic gastrectomy for gastric cancer using the hinotori™ surgical robot system.
PubMed 文献 · Surg Endosc · 2024-02-08

单中心回顾性研究纳入2022年11月至2023年10月共24例胃癌患者,使用日本hinotori™手术机器人系统行机器人胃切除术,主要终点为术后30天内并发症率。结果显示无Clavien-Dindo IIIa级及以上并发症,2例(8.3%)发生II级并发症,无术中不良事件,全部实现R0切除,作者认为使用hinotori行胃癌标准淋巴结清扫的机器人胃切除术可安全实施。

要点

  • 24例胃癌患者使用hinotori行机器人胃切除术,无Clavien-Dindo IIIa级及以上并发症。
  • 2例(8.3%)发生II级并发症(肠炎和肺炎),无术中不良事件及中转。
  • 全部患者实现R0切除,中位术中时间400分钟、出血量14.5 mL、清扫淋巴结51.5枚。

核心结论

  • 作者认为,使用hinotori对胃癌行标准淋巴结清扫的机器人胃切除术可安全实施。

研究设计与样本

  • 单中心回顾性研究,2022年11月至2023年10月共纳入24例胃癌患者,行hinotori机器人胃切除术,主要终点为术后30天内并发症率。

主要发现

  • 24例中男性16例(66.7%),中位年龄73.5岁,中位体重指数22.9 kg/m2。
  • 23例(95.8%)肿瘤位于胃中下部,临床I期16例(66.7%)、II期7例(29.2%),23例(95.8%)行远端胃切除术。
  • 无Clavien-Dindo IIIa级及以上并发症,2例(8.3%)发生II级并发症(肠炎和肺炎);无术中不良事件包括中转。
  • 全部患者实现R0切除;中位术中时间和控制台时间分别为400分钟和305分钟,中位出血量14.5 mL,清扫淋巴结数51.5枚。

临床怎么用

  • 作者认为使用hinotori行胃癌标准淋巴结清扫的机器人胃切除术可安全实施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the da Vinci™ Surgical System is the most predominantly used surgical robot worldwide, other surgical robots are being developed. The Japanese surgical robot hinotori™ Surgical Robot System was launched and approved for clinical use in Japan in November 2022. We performed the first robotic gastrectomy for gastric cancer using hinotori in the world. Here, we report our initial experience and evaluation of the feasibility and safety of robotic gastrectomy for gastric cancer using hinotori. METHODS: A single-institution retrospective study was conducted. Between November 2022 and October 2023, 24 patients with gastric cancer underwent robotic gastrectomy with hinotori. Five ports, including one for an assistant, were placed in the upper abdomen, and gastric resection with standard lymphadenectomy and intracorporeal reconstruction were performed. The primary endpoint was the postoperative complication rate within 30 days after surgery. The secondary outcomes were surgical outcomes, including intraoperative adverse events, operative time, blood loss, and the number of dissected nodes. RESULTS: Of the 24 patients, 16 (66.7%) were male. The median age and body mass index were 73.5 years and 22.9 kg/m2, respectively. Twenty-three patients (95.8%) had tumors in the middle to lower stomach. Sixteen (66.7%) and seven (29.2%) patients had clinical stage I and II diseases, respectively. Twenty-three (95.8%) patients underwent distal gastrectomy. No patient had postoperative complications of Clavien-Dindo classification IIIa or higher, whereas two (8.3%) had the grade II complications (enteritis and pneumonia). No intraoperative adverse events, including conversion to other approaches, were observed. All patients received R0 resection. The median operative and console times were 400 and 305 min, respectively. The median blood loss was 14.5 mL, and the number of lymph nodes dissected was 51.5. CONCLUSIONS: This study found that robotic gastrectomy with standard lymphadenectomy for gastric cancer using hinotori can be safely performed.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Inoue S, Nakauchi M, Umeki Y, et al. First clinical experiences of robotic gastrectomy for gastric cancer using the hinotori™ surgical robot system. Surg Endosc. 2024. PMID: 38332175. doi:10.1007/s00464-024-10695-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。